The changing landscape in MRCC
Multiple agents recommended but not
Current Challenges
Len +
Sunitinib
Temsirolimus
Pazopanib
Beva + IFNa
prioritised
No biomarkers exist to guide patient
selection
Eve
Sorafenib
Axitinib
Everolimus
Optimal sequence not defined
Complete response is rare
Nivolumab
Cabozantinib
No cure so far
Escudier et al. Ann Oncol 2016
